The NeoALTTO clinical trial was a phase three randomized clinical trial designed to assess the efficacy of anti-HER2 monoclonal antibody trastuzumab, the tyrosine kinase inhibitor lapatinib, and their combination therapies on HER2-overexpressing breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.